Navigation Links
Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Date:10/3/2007

PRINCETON, N.J., Oct. 3 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) has commenced dosing in a Phase 1 study of R7128 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in up to 75 treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. R7128 is a prodrug of PSI-6130, an oral cytidine nucleoside analog polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche. The purpose of this study is a preliminary evaluation of safety, tolerability, pharmacokinetics and antiviral activity of R7128 in the clinically-relevant setting of combination therapy with the current standard of care for chronic HCV infection.

The study will include two to three oral doses of R7128 (500 mg to 1500 mg) that will be administered twice-daily with Pegasys plus Copegus for 28 days. There will be 25 patients in each dose cohort with 20 patients randomized to receive R7128 and 5 patients randomized to receive placebo, all administered in combination with the standard of care. After completing 28 days of the triple combination regimen and a follow-up period of 4 weeks of Pegasys plus Copegus, all patients will then receive 40 weeks of open-label standard of care dosing under a separate protocol. Please see http://www.clinicaltrials.gov or e-mail clinicaltrials@pharmasset.com for more information.

"We are excited about the rapid pace of development of R7128, and the opportunity to evaluate its safety and potency in combination with the standard of care," stated Dr. Michelle Berrey, Pharmasset's Vice President, Clinical Develo
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 According ... Development Market by Product (Equipment, Media and Reagents), by ... & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) ... by MarketsandMarkets, analyzes and studies the major market ... Browse 114 market data tables and 64 figures ...
(Date:9/22/2014)... 22, 2014 Research and Markets  has ... Diclofenac Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... a focus on the Chinese situation. The ... definitions, classifications, applications and industry chain structure. The diclofenac ...
(Date:9/22/2014)... , Sept. 22, 2014 CytRx Corporation ... development company specializing in oncology, today announced that study ... clinical trials of aldoxorubicin, a pivotal global Phase 3 ... a global Phase 2b clinical trial in small cell ... for Medical Oncology (ESMO) 2014 Congress being held September ...
Breaking Medicine Technology:Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4Global and Chinese Diclofenac Industry Report 2014 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6
(Date:9/22/2014)... 22, 2014 Oregon Governor John ... as “Oregon Chiropractic Health and Wellness Month.” , ... (UWS) celebrates 110 years of leadership in educating ... was the first educational institution offering a doctor ... expanded over the past 110 years and now ...
(Date:9/22/2014)... Jose, California (PRWEB) September 22, 2014 ... Respiratory care market occupies a significant presence in ... the most widespread healthcare problems globally. Key factors ... unhealthy lifestyle habits such as smoking; increasing levels ... COPD; and expanding base of aging population vulnerable ...
(Date:9/22/2014)... The Spa Standard, announced today that Jenny ... in developing content and courses for their online social ... 15 years of experience in massage therapy, esthetics, day ... companies including Orient Express Hotels and the Capella Hotel ... Jenny gained extensive industry insight through planning, staffing, training ...
(Date:9/22/2014)... 22, 2014 The American Association for Thoracic ... the prevention and treatment of perioperative and postoperative ... procedures. The guidelines are published in The ... "These guidelines have the potential to prevent the ... who undergo lung surgery in the United States ...
(Date:9/22/2014)... can enhance the ability of the bacterium Streptococcus ... to research published ahead of print in the journal ... study, the investigators infected mice with either influenza alone, ... the populations of bacteria and virus over time. They ... infection. , Influenza infection enhanced the bacterium,s ability ...
Breaking Medicine News(10 mins):Health News:Oregon Governor Proclaims October as “Chiropractic Month” – UWS Brought Chiropractic Health Care to Oregon in 1904 2Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Rising Incidence of Respiratory Diseases to Drive the Respiratory Care Equipment and Supplies Market, According to New Report by Global Industry Analysts, Inc. 4Health News:The Spa Standard Appoints Vice-President of Content and Course Development 2Health News:New guidelines issued for managing peri- and postoperative atrial fibrillation 2Health News:New guidelines issued for managing peri- and postoperative atrial fibrillation 3Health News:New guidelines issued for managing peri- and postoperative atrial fibrillation 4Health News:Influenza A potentiates pneumococcal co-infection: New details emerge 2
... ... ... ... ...
... ... ... ... ...
... , ... ... ... ...
... ... custom stress balls has started 2010 with two record months which points to an economic ... ... balls has started 2010 with two record months which points to an economic upturn ...
... ctp ... this means for leadership and how it is redefining our understanding of soft skills. ... – all leading to better organisations and higher returns on human investment. , ... (PRWEB) March 2, 2010 ...
... Clinically Relevant Technologies ... management guidelines with the release of new medical iPhone app. , ... (PRWEB) March 2, 2010 -- Clinically Relevant Technologies released a new ... care gap. The release comes on the heels of a study published last month in ...
Cached Medicine News:Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 2Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 3Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 4Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 5Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 6Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 7Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 8Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 9Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 10Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 11Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 12Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 13Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 14Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 2Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 3Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 2Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 3Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 5Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 6Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 7Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 8Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 9Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 10Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 11Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 12Health News:Promotional Stress Ball Supplier -- StressBallsUK.com Starts 2010 Strongest Ever 2Health News:Key Leadership Seminar: Maximizing Profit through Social Intelligence - What Neuroscience Tells Us 2Health News:Clinically Relevant Technologies Releases New Medical iPhone App To Fill Gap In Adherence To Low Back Pain Management Guidelines 2
... Introduction of the Selenia full ... beginning of a new era in ... of elegance and innovation combines the ... with sophisticated information management capabilities to ...
... The Stellate Harmonie workstation is a ... processing loads, high quality video capability, and ... recording and review functions A framework that ... and archiving of data A centralized database ...
... features is the PupilFit software which automatically ... the pupil images, producing accurate, repeatable measurements ... circle is shown as a dotted line ... measurement ismeaningful, and not just a number ...
Dual-sided, Interhemispheric Grid Electrode with 16 Contact Leads; Cortical Grid Electrode with 16 Contact Leads; Pediatric Grid Electrode with Flex Connector, 0.5 cm spacing...
Medicine Products: